• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SelectQuote, Inc. Reports Second Quarter of Fiscal Year 2026 Results

    2/5/26 7:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance
    Get the next $SLQT alert in real time by email

    Second Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights

    • Revenue of $537.1 million
    • Net income of $69.3 million
    • Adjusted EBITDA* of $84.7 million

    Fiscal Year 2026 Guidance Ranges:

    • Revenue expected in a range of $1.61 billion to $1.71 billion
    • Adjusted EBITDA* expected in a range of $90 million to $100 million

    Second Quarter Fiscal Year 2026 – Segment Highlights

    Senior

    • Revenue of $261.5 million
    • Adjusted EBITDA of $102.5 million
    • Approved Medicare Advantage policies of 257,279

    Healthcare Services

    • Revenue of $230.7 million
    • Adjusted EBITDA of $0.8 million
    • 113,483 SelectRx members

    Life

    • Revenue of $43.6 million
    • Adjusted EBITDA of $5.6 million

     

    SelectQuote, Inc. (NYSE:SLQT) reported consolidated revenue for the second quarter of fiscal year 2026 of $537.1 million compared to consolidated revenue for the second quarter of fiscal year 2025 of $481.1 million. Consolidated net income for the second quarter of fiscal year 2026 was $69.3 million compared to consolidated net income for the second quarter of fiscal year 2025 of $53.2 million. Finally, consolidated Adjusted EBITDA* for the second quarter of fiscal year 2026 was $84.7 million compared to consolidated Adjusted EBITDA* for the second quarter of fiscal year 2025 of $87.5 million.

    Tim Danker, SelectQuote Chief Executive Officer, "This year's AEP again highlighted the strength and consistency of SelectQuote's operating model. Despite continued volatility in Medicare Advantage benefit structures, our team delivered another season of high‑quality execution, with strong agent productivity and marketing efficiency driving 39% Adjusted EBITDA* margins for our Senior business. At the same time, our rapidly growing Healthcare Services segment, led by SelectRx, continues to provide meaningful clinical value for members and attractive long‑term economics for our platform. The combination of improved medication adherence, lower waste, and better patient outcomes reinforces SelectRx as an increasingly important driver of value creation for the company and broader pharmacy ecosystem.

    Our revised fiscal 2026 guidance reflects two discrete, partner‑driven headwinds: a national carrier's decision to constrain additional MA policy volume by curtailing strategic marketing spend across all channels, and the previously communicated PBM reimbursement changes. Neither impact related to our internal performance, which remained strong. While these developments are frustrating, they do not alter our conviction in the long‑term earnings power of SelectQuote's comprehensive healthcare platform.

    What continues to give us confidence is the consistency of our underlying operational execution. Regardless of the market backdrop, our teams have demonstrated the ability to drive efficiency, deliver value for partners and beneficiaries, and maintain strong margin discipline. Coupled with our improved balance sheet flexibility, we believe this operational consistency positions SelectQuote to deliver meaningful cash‑flow generation for shareholders in the quarters and years ahead."

    * See "Non-GAAP Financial Measures" below.

    Segment Results

    We currently have three reportable segments: 1) Senior, 2) Healthcare Services and 3) Life. The performance measures of the segments include total revenue and adjusted EBITDA. Costs of commissions and other services revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount.

    Senior

    Financial Results

    The following table provides the financial results for the Senior segment for the periods presented:

     

    Three Months Ended

    December 31,

     

     

    Six Months Ended

    December 31,

     

    (in thousands)

     

    2025

     

     

     

    2024

     

     

    % Change

     

    2025

     

     

     

    2024

     

     

    % Change

    Revenue

    $

    261,539

     

     

    $

    255,578

     

     

    2%

    $

    320,536

     

     

    $

    348,487

     

     

    (8)%

    Adjusted EBITDA

     

    102,452

     

     

     

    100,521

     

     

    2%

     

    81,415

     

     

     

    108,247

     

     

    (25)%

    Adjusted EBITDA Margin

     

    39

    %

     

     

    39

    %

     

     

     

    25

    %

     

     

    31

    %

     

     

    Operating Metrics

    Submitted Policies

    Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to the agent to submit the application to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier.

    The following table shows the number of submitted policies for the periods presented:

     

    Three Months Ended

    December 31,

     

     

     

    Six Months Ended

    December 31,

     

     

     

    2025

     

    2024

     

    % Change

     

    2025

     

    2024

     

    % Change

    Medicare Advantage

    286,076

     

    284,774

     

    —%

    356,316

     

    387,055

     

    (8)%

    All other (1)

    29,546

     

    26,861

     

    10%

    46,720

     

    43,117

     

    8%

    Total

    315,622

     

    311,635

     

    1%

    403,036

     

    430,172

     

    (6)%

    (1) Represents the submitted policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

    Approved Policies

    Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.

    The following table shows the number of approved policies for the periods presented:

     

    Three Months Ended

    December 31,

     

     

     

    Six Months Ended

    December 31,

     

     

     

    2025

     

    2024

     

    % Change

     

    2025

     

    2024

     

    % Change

    Medicare Advantage

    257,279

     

    247,849

     

    4%

    319,789

     

    339,529

     

    (6)%

    All other (1)

    20,302

     

    19,714

     

    3%

    34,178

     

    32,693

     

    5%

    Total

    277,581

     

    267,563

     

    4%

    353,967

     

    372,222

     

    (5)%

    (1) Represents the approved policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

    Lifetime Value of Commissions per Approved Policy

    Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions.

    The following table shows the lifetime value of commissions per approved policy for the periods presented:

     

    Three Months Ended

    December 31,

     

     

     

    Six Months Ended

    December 31,

     

     

    (dollars per policy):

     

    2025

     

     

    2024

     

    % Change

     

     

    2025

     

     

    2024

     

    % Change

    Medicare Advantage

    $

    874

     

    $

    907

     

    (4)%

    $

    853

     

    $

    881

     

    (3)%

    All other(1)

     

    151

     

     

    111

     

    36%

     

    145

     

     

    134

     

    8%

    (1) Represents the weighted average LTV per approved policy.

    Healthcare Services

    Financial Results

    The following table provides the financial results for the Healthcare Services segment for the periods presented:

     

    Three Months Ended

    December 31,

     

     

     

    Six Months Ended

    December 31,

     

     

    (in thousands)

     

    2025

     

     

     

    2024

     

     

    % Change

     

     

    2025

     

     

     

    2024

     

     

    % Change

    Revenue

    $

    230,654

     

     

    $

    183,370

     

     

    26%

    $

    452,005

     

     

    $

    339,108

     

     

    33%

    Adjusted EBITDA

     

    846

     

     

     

    2,212

     

     

    (62)%

     

    8,058

     

     

     

    7,089

     

     

    14%

    Adjusted EBITDA Margin

     

    —

    %

     

     

    1

    %

     

     

     

    2

    %

     

     

    2

    %

     

     

    Operating Metrics

    Members

    The total number of SelectRx members represents the amount of active customers to which an order has been shipped and the prescriptions per day represents the total average prescriptions shipped per business day. These two metrics are the primary drivers of revenue for Healthcare Services.

    The following table shows the total number of SelectRx members as of the periods presented:

     

     

    December 31, 2025

     

    December 31, 2024

    Total SelectRx Members

     

    113,483

     

    96,695

    The total number of SelectRx members increased by 17% as of December 31, 2025, compared to December 31, 2024, due to our strategy to grow SelectRx membership.

    The following table shows the average prescriptions shipped per day for the periods presented:

     

     

    Three Months Ended

    December 31,

     

    Six Months Ended

    December 31,

     

     

    2025

     

    2024

     

    2025

     

    2024

    Prescriptions Per Day

     

    32,578

     

    26,846

     

    31,978

     

    25,922

    Combined Senior and Healthcare Services - Consumer Per Unit Economics

    Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.

    The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents' core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company's reassessment of its cohorts' transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost ("CAC") multiple represents total revenue as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.

    The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.

     

    Twelve Months Ended December 31,

    (dollars per approved policy):

     

    2025

     

     

     

    2024

     

    MA and MS approved policies

     

    575,181

     

     

     

    634,135

     

    MA and MS commission per MA / MS policy

    $

    870

     

     

    $

    909

     

    Other commission per MA/MS policy

     

    13

     

     

     

    12

     

    Pharmacy revenue per MA/MS policy

     

    1,463

     

     

     

    938

     

    Other revenue per MA/MS policy

     

    136

     

     

     

    153

     

    Total revenue per MA / MS policy

     

    2,482

     

     

     

    2,012

     

    Total operating expenses per MA / MS policy

     

    (2,202

    )

     

     

    (1,685

    )

    Adjusted EBITDA per MA/MS policy

    $

    280

     

     

    $

    327

     

    Adjusted EBITDA Margin per MA/MS policy

     

    11

    %

     

     

    16

    %

    Revenue / CAC multiple

    6.5X

     

    5.3X

    Total revenue per MA/MS policy increased 23% for the twelve months ended December 31, 2025, compared to the twelve months ended December 31, 2024, primarily due to the increase in pharmacy revenue. Total operating expenses per MA/MS policy increased 31% for the twelve months ended December 31, 2025, compared to the twelve months ended December 31, 2024, driven by an increase in cost of goods sold-pharmacy revenue for Healthcare Services due to the growth of the business.

    Life

    Financial Results

    The following table provides the financial results for the Life segment for the periods presented:

     

    Three Months Ended

    December 31,

     

     

     

    Six Months Ended

    December 31,

     

     

    (in thousands)

     

    2025

     

     

     

    2024

     

     

    % Change

     

     

    2025

     

     

     

    2024

     

     

    % Change

    Revenue

    $

    43,623

     

     

    $

    39,861

     

     

    9%

    $

    90,269

     

     

    $

    79,151

     

     

    14%

    Adjusted EBITDA

     

    5,581

     

     

     

    7,423

     

     

    (25)%

     

    11,152

     

     

     

    13,383

     

     

    (17)%

    Adjusted EBITDA Margin

     

    13

    %

     

     

    19

    %

     

     

     

    12

    %

     

     

    17

    %

     

     

    Operating Metrics

    Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.

    The following table shows term and final expense premiums for the periods presented:

     

    Three Months Ended

    December 31,

     

     

     

    Six Months Ended

    December 31,

     

     

    (in thousands)

     

    2025

     

     

    2024

     

    % Change

     

     

     

    2025

     

     

    2024

     

    % Change

    Term Premiums

    $

    17,513

     

    $

    17,311

     

    1%

     

    $

    36,957

     

    $

    32,529

     

    14%

    Final Expense Premiums

     

    27,355

     

     

    22,139

     

    24%

     

     

    56,784

     

     

    46,612

     

    22%

    Total

    $

    44,868

     

    $

    39,450

     

    14%

     

    $

    93,741

     

    $

    79,141

     

    18%

    Earnings Conference Call

    SelectQuote, Inc. will host a conference call with the investment community on February 5, 2025 beginning at 8:00 a.m. ET. To register for this conference call, please use this link: https://events.q4inc.com/analyst/199368355?pwd=c0a3KINj. After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx.

    Non-GAAP Financial Measures

    This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA, which, when presented on a consolidated basis, is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to any similarly titled measure presented by other companies. We define Adjusted EBITDA as net income (loss) plus interest expense, income taxes, depreciation and amortization, changes in fair value of warrant liabilities, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income (loss). We monitor and have presented in this release Adjusted EBITDA because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, establish budgets, and develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.

    A reconciliation of the differences between Adjusted EBITDA and its most directly comparable GAAP measure, net income (loss), is presented below on page 15. The Company is unable to provide a quantitative reconciliation of forward-looking Adjusted EBITDA to its most directly comparable GAAP measure without unreasonable effort because it is not possible to predict certain information included in the calculation of such GAAP measure, including the fair value of outstanding warrants to purchase shares of the Company's common stock. The unavailable information could have a significant impact on the Company's GAAP financial results.

    Forward Looking Statements

    This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as "may," "should," "could," "predict," "potential," "believe," "will likely result," "expect," "continue," "will," "anticipate," "seek," "estimate," "intend," "plan," "projection," "would" and "outlook," or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; potential litigation and other legal proceedings or inquiries; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers' approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, changes in reimbursement rates under our contracts with pharmacy benefit managers, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled "Risk Factors" in the most recent Annual Report on Form 10-K (the "Annual Report") and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

    About SelectQuote:

    Founded in 1985, SelectQuote (NYSE:SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote's success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.

    With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

     

    SELECTQUOTE, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Unaudited)

    (In thousands)

     

     

    December 31, 2025

     

    June 30, 2025

    ASSETS

     

     

     

    CURRENT ASSETS:

     

     

     

    Cash, cash equivalents, and restricted cash

    $

    22,201

     

    $

    35,733

    Accounts receivable, net of allowances of $9.6 million and $11.8 million, respectively

     

    127,647

     

     

    151,388

    Commissions receivable-current

     

    253,039

     

     

    132,077

    Other current assets

     

    21,928

     

     

    21,844

    Total current assets

     

    424,815

     

     

    341,042

    COMMISSIONS RECEIVABLE—Net

     

    840,739

     

     

    818,751

    PROPERTY AND EQUIPMENT—Net

     

    14,668

     

     

    14,577

    SOFTWARE—Net

     

    16,209

     

     

    15,060

    OPERATING LEASE RIGHT-OF-USE ASSETS

     

    22,603

     

     

    24,635

    INTANGIBLE ASSETS—Net

     

    1,404

     

     

    1,973

    GOODWILL

     

    29,438

     

     

    29,438

    OTHER ASSETS

     

    2,383

     

     

    3,880

    TOTAL ASSETS

    $

    1,352,259

     

    $

    1,249,356

     

     

     

     

    LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS' EQUITY

     

     

     

    CURRENT LIABILITIES:

     

     

     

    Accounts payable

    $

    80,433

     

    $

    59,205

    Accrued expenses

     

    57,477

     

     

    13,856

    Accrued compensation and benefits

     

    62,209

     

     

    58,788

    Operating lease liabilities—current

     

    4,887

     

     

    4,820

    Current portion of long-term debt

     

    20,104

     

     

    68,523

    Contract liabilities

     

    1,837

     

     

    698

    Other current liabilities

     

    7,829

     

     

    7,020

    Total current liabilities

     

    234,776

     

     

    212,910

    LONG-TERM DEBT, NET—less current portion

     

    385,692

     

     

    316,589

    DEFERRED INCOME TAXES

     

    42,091

     

     

    37,872

    OPERATING LEASE LIABILITIES

     

    23,575

     

     

    25,982

    OTHER LIABILITIES

     

    46,482

     

     

    80,485

    Total liabilities

     

    732,616

     

     

    673,838

     

     

     

     

    COMMITMENTS AND CONTINGENCIES

     

     

     

    PREFERRED STOCK:

     

     

     

    Senior Non-Convertible Preferred Stock, $0.01 par value, 350,000 shares issued

    and outstanding as of December 31, 2025 and June 30, 2025, respectively, current liquidation

    preference of $394.2 million and $367.1 million as of December 31, 2025 and June 30, 2025.

     

    259,981

     

     

    224,374

    SHAREHOLDERS' EQUITY:

     

     

     

    Common stock, $0.01 par value

     

    1,763

     

     

    1,728

    Additional paid-in capital

     

    541,254

     

     

    571,605

    Accumulated deficit

     

    (183,355)

     

     

    (222,189)

    Total shareholders' equity

     

    359,662

     

     

    351,144

    TOTAL LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS' EQUITY

    $

    1,352,259

     

    $

    1,249,356

     

    SELECTQUOTE, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

    (Unaudited)

    (In thousands)

     

     

    Three Months Ended

    December 31,

     

    Six Months Ended

    December 31,

     

     

    2025

     

     

    2024

     

     

    2025

     

     

    2024

    REVENUE:

     

     

     

     

     

     

     

    Commissions and other services

    $

    309,893

     

    $

    301,069

     

    $

    420,160

     

    $

    440,449

    Pharmacy

     

    227,209

     

     

    180,000

     

     

    445,753

     

     

    332,883

    Total revenue

     

    537,102

     

     

    481,069

     

     

    865,913

     

     

    773,332

     

     

     

     

     

     

     

     

    OPERATING COSTS AND EXPENSES:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    103,034

     

     

    101,138

     

     

    172,135

     

     

    166,872

    Cost of goods sold—pharmacy revenue

     

    205,194

     

     

    156,201

     

     

    397,973

     

     

    285,724

    Marketing and advertising

     

    105,028

     

     

    97,725

     

     

    166,975

     

     

    161,489

    Selling, general, and administrative

     

    38,940

     

     

    45,021

     

     

    74,759

     

     

    81,166

    Technical development

     

    9,595

     

     

    10,044

     

     

    19,506

     

     

    19,119

    Total operating costs and expenses

     

    461,791

     

     

    410,129

     

     

    831,348

     

     

    714,370

     

     

     

     

     

     

     

     

    INCOME FROM OPERATIONS

     

    75,311

     

     

    70,940

     

     

    34,565

     

     

    58,962

     

     

     

     

     

     

     

     

    INTEREST EXPENSE, NET

     

    (11,613)

     

     

    (23,721)

     

     

    (23,421)

     

     

    (46,752)

    CHANGE IN FAIR VALUE OF WARRANTS

     

    19,296

     

     

    (7,642)

     

     

    34,332

     

     

    (7,642)

    OTHER EXPENSE, NET

     

    (39)

     

     

    (21)

     

     

    (183)

     

     

    (32)

    INCOME BEFORE INCOME TAX EXPENSE (BENEFIT)

     

    82,955

     

     

    39,556

     

     

    45,293

     

     

    4,536

    INCOME TAX EXPENSE (BENEFIT)

     

    13,662

     

     

    (13,680)

     

     

    6,459

     

     

    (4,154)

     

     

     

     

     

     

     

     

    NET INCOME

    $

    69,293

     

    $

    53,236

     

    $

    38,834

     

    $

    8,690

    Senior Non-Convertible Preferred Stock accumulated dividends and accretion

     

    (18,125)

     

     

    —

     

    $

    (35,607)

     

    $

    —

    NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS

    $

    51,168

     

    $

    53,236

     

    $

    3,227

     

    $

    8,690

     

     

     

     

     

     

     

     

    NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS PER SHARE:

     

     

     

     

     

     

     

    Basic

    $

    0.27

     

    $

    0.31

     

    $

    0.02

     

    $

    0.05

    Diluted

    $

    0.26

     

    $

    0.30

     

    $

    0.01

     

    $

    0.05

     

     

     

     

     

     

     

     

    WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS:

     

     

     

     

     

     

     

    Basic

     

    187,573

     

     

    171,802

     

     

    186,694

     

     

    171,116

    Diluted

     

    190,830

     

     

    175,101

     

     

    190,730

     

     

    175,024

     

     

     

     

     

     

     

     

    OTHER COMPREHENSIVE LOSS, NET OF TAX:

     

     

     

     

     

     

     

    Unrealized loss, net of related tax benefit for the three and six months ended December 31, 2025,

    and 2024, of $0.0 million and $0.1 million

     

    —

     

     

    (393)

     

     

    —

     

     

    (432)

    Amount reclassified into earnings, net of related tax benefit for the three months ended

    December 31, 2025, and 2024, of $0.0 million and $0.3 million, and for the six months ended

    December 31, 2025, and 2024, of $0.0 million and $1.3 million.

     

    —

     

     

    (934)

     

     

    —

     

     

    (3,680)

    OTHER COMPREHENSIVE LOSS

     

    —

     

     

    (1,327)

     

     

    —

     

     

    (4,112)

    COMPREHENSIVE INCOME

    $

    69,293

     

    $

    51,909

     

    $

    38,834

     

    $

    4,578

     

    SELECTQUOTE, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Unaudited)

    (In thousands)

     

     

    Six Months Ended December 31,

     

     

    2025

     

     

    2024

    CASH FLOWS FROM OPERATING ACTIVITIES:

     

     

     

    Net income

    $

    38,834

     

    $

    8,690

    Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash used in

    operating activities:

     

     

     

    Depreciation and amortization

     

    8,622

     

     

    10,659

    Loss on disposal of property, equipment, and software

     

    —

     

     

    157

    Impairment of equity-method investment

     

    1,000

     

     

    —

    Share-based compensation expense

     

    7,802

     

     

    8,545

    Deferred income taxes

     

    4,220

     

     

    (4,154)

    Amortization of debt issuance costs and debt discount

     

    2,446

     

     

    2,379

    Write-off of debt issuance costs

     

    —

     

     

    93

    Accrued interest payable in kind

     

    —

     

     

    9,673

    Change in fair value of warrants

     

    (34,332)

     

     

    7,642

    Non-cash lease expense

     

    2,033

     

     

    1,846

    Bad debt expense

     

    —

     

     

    4,203

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable, net

     

    23,741

     

     

    30,038

    Commissions receivable

     

    (142,950)

     

     

    (155,507)

    Other assets

     

    226

     

     

    (4,802)

    Accounts payable and accrued expenses

     

    63,628

     

     

    46,211

    Operating lease liabilities

     

    (2,341)

     

     

    (2,285)

    Other liabilities

     

    5,500

     

     

    (8,692)

    Net cash used in operating activities

     

    (21,571)

     

     

    (45,304)

    CASH FLOWS FROM INVESTING ACTIVITIES:

     

     

     

    Purchases of property and equipment

     

    (2,146)

     

     

    (741)

    Purchases of software and capitalized software development costs

     

    (5,485)

     

     

    (4,105)

    Net cash used in investing activities

     

    (7,631)

     

     

    (4,846)

    CASH FLOWS FROM FINANCING ACTIVITIES:

     

     

     

    Proceeds from revolving credit facility

     

    257,000

     

     

    84,900

    Payments on revolving credit facility

     

    (219,000)

     

     

    (26,900)

    Payments on Term Loans

     

    (9,646)

     

     

    (123,215)

    Proceeds from ABS Notes

     

    —

     

     

    99,095

    Payments on ABS Notes

     

    (10,054)

     

     

    (6,272)

    Payments on other debt

     

    (243)

     

     

    (114)

    Proceeds from common stock options exercised and employee stock purchase plan

     

    —

     

     

    38

    Payments of tax withholdings related to net share settlement of equity awards

     

    (2,511)

     

     

    (3,960)

    Payments of debt issuance costs

     

    (72)

     

     

    (2,479)

    Net cash provided by financing activities

     

    15,474

     

     

    21,093

    NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

     

    (13,728)

     

     

    (29,057)

    CASH, CASH EQUIVALENTS AND RESTRICTED CASH —Beginning of period

     

    37,066

     

     

    42,690

    CASH, CASH EQUIVALENTS AND RESTRICTED CASH —End of period

    $

    23,338

     

    $

    13,633

     

    SELECTQUOTE, INC. AND SUBSIDIARIES

    Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense (benefit)

    (Unaudited)

     

     

    Three Months Ended December 31, 2025

    (in thousands)

    Senior

     

    Healthcare

    Services

     

    Life

     

    Consolidated

    Total revenue from reportable segments

    $

    261,539

     

    $

    230,654

     

    $

    43,623

     

    $

    535,816

    Less:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    (74,391)

     

     

    (8,357)

     

     

    (17,404)

     

     

    Cost of goods sold - pharmacy revenue

     

    —

     

     

    (203,783)

     

     

    —

     

     

    Marketing expense

     

    (84,056)

     

     

    (2,235)

     

     

    (20,376)

     

     

    Technical development

     

    —

     

     

    (311)

     

     

    —

     

     

    Selling, general, and administrative

     

    (640)

     

     

    (15,122)

     

     

    (262)

     

     

    Adjusted Segment EBITDA

    $

    102,452

     

    $

    846

     

    $

    5,581

     

    $

    108,879

    Reconciliation of total segment Adjusted EBITDA

     

     

     

     

     

     

     

    All other Adjusted EBITDA

     

     

     

     

     

     

     

    2,102

    Corporate

     

     

     

     

     

     

     

    (26,250)

    Share-based compensation expense

     

     

     

     

     

     

     

    (3,475)

    Transaction costs

     

     

     

     

     

     

     

    (662)

    Depreciation and amortization

     

     

     

     

     

     

     

    (4,322)

    Impairment of equity-method investment

     

     

     

     

     

     

     

    (1,000)

    Change in fair value of warrants

     

     

     

     

     

     

     

    19,296

    Interest expense, net

     

     

     

     

     

     

     

    (11,613)

    Income before income tax expense (benefit)

     

     

     

     

     

     

    $

    82,955

     

     

    Three Months Ended December 31, 2024

    (in thousands)

    Senior

     

    Healthcare

    Services

     

    Life

     

    Consolidated

    Total revenue from reportable segments

    $

    255,578

     

    $

    183,370

     

    $

    39,861

     

    $

    478,809

    Less:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    (75,042)

     

     

    (7,932)

     

     

    (15,041)

     

     

    Cost of goods sold - pharmacy revenue

     

    —

     

     

    (155,009)

     

     

    —

     

     

    Marketing expense

     

    (79,398)

     

     

    (1,902)

     

     

    (17,172)

     

     

    Technical development

     

    —

     

     

    (592)

     

     

    —

     

     

    Selling, general, and administrative

     

    (617)

     

     

    (15,723)

     

     

    (225)

     

     

    Adjusted Segment EBITDA

    $

    100,521

     

    $

    2,212

     

    $

    7,423

     

    $

    110,156

    Reconciliation of total segment Adjusted EBITDA

     

     

     

     

     

     

     

    All other Adjusted EBITDA

     

     

     

     

     

     

     

    2,303

    Corporate

     

     

     

     

     

     

     

    (24,940)

    Share-based compensation expense

     

     

     

     

     

     

     

    (4,699)

    Transaction costs

     

     

     

     

     

     

     

    (6,719)

    Depreciation and amortization

     

     

     

     

     

     

     

    (5,060)

    Loss on disposal of property, equipment, and software, net

     

     

     

     

     

     

     

    (122)

    Change in fair value of warrants

     

     

     

     

     

     

     

    (7,642)

    Interest expense, net

     

     

     

     

     

     

     

    (23,721)

    Income before income tax expense (benefit)

     

     

     

     

     

     

    $

    39,556

     

     

    Six Months Ended December 31, 2025

    (in thousands)

    Senior

     

    Healthcare

    Services

     

    Life

     

    Consolidated

    Total revenue from reportable segments

    $

    320,536

     

    $

    452,005

     

    $

    90,269

     

    $

    862,810

    Less:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    (116,288)

     

     

    (14,658)

     

     

    (35,382)

     

     

    Cost of goods sold - pharmacy revenue

     

    —

     

     

    (395,181)

     

     

    —

     

     

    Marketing expense

     

    (121,686)

     

     

    (4,623)

     

     

    (43,136)

     

     

    Technical development

     

    —

     

     

    (749)

     

     

    —

     

     

    Selling, general, and administrative

     

    (1,147)

     

     

    (28,736)

     

     

    (599)

     

     

    Adjusted Segment EBITDA

    $

    81,415

     

    $

    8,058

     

    $

    11,152

     

    $

    100,625

    Reconciliation of total segment Adjusted EBITDA

     

     

     

     

     

     

     

    All other Adjusted EBITDA

     

     

     

     

     

     

     

    3,989

    Corporate

     

     

     

     

     

     

     

    (51,962)

    Share-based compensation expense

     

     

     

     

     

     

     

    (7,802)

    Transaction costs

     

     

     

     

     

     

     

    (846)

    Depreciation and amortization

     

     

     

     

     

     

     

    (8,622)

    Impairment of equity-method investment

     

     

     

     

     

     

     

    (1,000)

    Change in fair value of warrants

     

     

     

     

     

     

     

    34,332

    Interest expense, net

     

     

     

     

     

     

     

    (23,421)

    Income before income tax expense (benefit)

     

     

     

     

     

     

    $

    45,293

     

     

    Six Months Ended December 31, 2024

    (in thousands)

    Senior

     

    Healthcare

    Services

     

    Life

     

    Consolidated

    Total revenue from reportable segments

    $

    348,487

     

    $

    339,108

     

    $

    79,151

     

    $

    766,746

    Less:

     

     

     

     

     

     

     

    Cost of commissions and other services revenue

     

    (116,169)

     

     

    (13,812)

     

     

    (29,613)

     

     

    Cost of goods sold - pharmacy revenue

     

    —

     

     

    (283,375)

     

     

    —

     

     

    Marketing expense

     

    (122,775)

     

     

    (4,149)

     

     

    (35,667)

     

     

    Technical development

     

    —

     

     

    (1,200)

     

     

    —

     

     

    Selling, general, and administrative

     

    (1,296)

     

     

    (29,483)

     

     

    (488)

     

     

    Adjusted Segment EBITDA

    $

    108,247

     

    $

    7,089

     

    $

    13,383

     

    $

    128,719

    Reconciliation of total segment Adjusted EBITDA

     

     

     

     

     

     

     

    All other Adjusted EBITDA

     

     

     

     

     

     

     

    6,099

    Corporate

     

     

     

     

     

     

     

    (48,983)

    Share-based compensation expense

     

     

     

     

     

     

     

    (8,545)

    Transaction costs

     

     

     

     

     

     

     

    (7,544)

    Depreciation and amortization

     

     

     

     

     

     

     

    (10,659)

    Loss on disposal of property, equipment, and software, net

     

     

     

     

     

     

     

    (157)

    Change in fair value of warrants

     

     

     

     

     

     

     

    (7,642)

    Interest expense, net

     

     

     

     

     

     

     

    (46,752)

    Income before income tax expense (benefit)

     

     

     

     

     

     

    $

    4,536

     

    RECONCILIATION OF NON-GAAP MEASURE

     

    SELECTQUOTE, INC. AND SUBSIDIARIES

    Reconciliation of Net income to Adjusted EBITDA

    (Unaudited)

     

     

    Three Months Ended December 31,

     

    Six Months Ended December 31,

    (in thousands)

     

    2025

     

     

    2024

     

     

    2025

     

     

    2024

    Net income

    $

    69,293

     

    $

    53,236

     

    $

    38,834

     

    $

    8,690

    Share-based compensation expense

     

    3,475

     

     

    4,699

     

     

    7,802

     

     

    8,545

    Transaction costs

     

    662

     

     

    6,719

     

     

    846

     

     

    7,544

    Depreciation and amortization

     

    4,322

     

     

    5,060

     

     

    8,622

     

     

    10,659

    Loss on disposal of property, equipment, and software, net

     

    —

     

     

    122

     

     

    —

     

     

    157

    Impairment of equity-method investment

     

    1,000

     

     

    —

     

     

    1,000

     

     

    —

    Change in fair value of warrants

     

    (19,296)

     

     

    7,642

     

     

    (34,332)

     

     

    7,642

    Interest expense, net

     

    11,613

     

     

    23,721

     

     

    23,421

     

     

    46,752

    Income tax expense (benefit)

     

    13,662

     

     

    (13,680)

     

     

    6,459

     

     

    (4,154)

    Adjusted EBITDA

    $

    84,731

     

    $

    87,519

     

    $

    52,652

     

    $

    85,835

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260205193710/en/

    Investor Relations:

    Sloan Bohlen

    877-678-4083

    investorrelations@selectquote.com

    Media:

    Matt Gunter

    913-286-4931

    matt.gunter@selectquote.com

    Get the next $SLQT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLQT

    DatePrice TargetRatingAnalyst
    5/21/2025$2.75Hold
    Jefferies
    9/30/2024$4.50Buy
    Craig Hallum
    2/29/2024$5.00Outperform
    Noble Capital Markets
    4/1/2022$4.00Neutral
    Credit Suisse
    2/8/2022$9.00 → $5.00Equal Weight
    Barclays
    2/8/2022$13.00 → $3.00Sector Perform
    RBC Capital
    2/8/2022$20.00 → $4.00Overweight → Neutral
    Piper Sandler
    2/8/2022$14.00 → $4.00Outperform → Neutral
    Credit Suisse
    More analyst ratings

    $SLQT
    SEC Filings

    View All

    SEC Form 10-Q filed by SelectQuote Inc.

    10-Q - SelectQuote, Inc. (0001794783) (Filer)

    2/5/26 9:01:30 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SelectQuote, Inc. (0001794783) (Filer)

    2/5/26 7:08:35 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - SelectQuote, Inc. (0001794783) (Filer)

    1/12/26 8:04:47 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on SelectQuote with a new price target

    Jefferies initiated coverage of SelectQuote with a rating of Hold and set a new price target of $2.75

    5/21/25 8:59:27 AM ET
    $SLQT
    Specialty Insurers
    Finance

    Craig Hallum initiated coverage on SelectQuote with a new price target

    Craig Hallum initiated coverage of SelectQuote with a rating of Buy and set a new price target of $4.50

    9/30/24 8:47:10 AM ET
    $SLQT
    Specialty Insurers
    Finance

    Noble Capital Markets initiated coverage on SelectQuote with a new price target

    Noble Capital Markets initiated coverage of SelectQuote with a rating of Outperform and set a new price target of $5.00

    2/29/24 8:29:44 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SelectQuote, Inc. Reports Second Quarter of Fiscal Year 2026 Results

    Second Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights Revenue of $537.1 million Net income of $69.3 million Adjusted EBITDA* of $84.7 million Fiscal Year 2026 Guidance Ranges: Revenue expected in a range of $1.61 billion to $1.71 billion Adjusted EBITDA* expected in a range of $90 million to $100 million Second Quarter Fiscal Year 2026 – Segment Highlights Senior Revenue of $261.5 million Adjusted EBITDA of $102.5 million Approved Medicare Advantage policies of 257,279 Healthcare Services Revenue of $230.7 million Adjusted EBITDA of $0.8 million 113,483 SelectRx members Life Revenue of $43.6 million Adjusted EBITDA of $5.6

    2/5/26 7:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote to Release Fiscal Second Quarter 2026 Earnings on February 5

    SelectQuote, Inc. (NYSE:SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its fiscal second quarter 2026 financial results before market open on Thursday, February 5, 2026. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (February 5, 2026) at 8:00 am ET to discuss the results. We encourage interested parties to access the live webcast of the event via our investor relations website https://ir.selectquote.com/investor-home/default.aspx or via this link. For those interested in dialing into the conferen

    1/22/26 7:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    University of Kansas Study Shows e-Brokers Like SelectQuote Extend Rural Residents' Access to Medicare Advantage Plans

    Research finds e-brokers bring access to low-income seniors across a 10-state region; approximately 400,000 residents live in communities without a single licensed Medicare insurance agent E-brokers greatly expand opportunities for rural residents to obtain health insurance through Medicare Advantage plans, according to a new study conducted by researchers at the University of Kansas in collaboration with SelectQuote, Inc. (NYSE:SLQT). The KU research analyzed data across 10 rural states and found that there are approximately 400,000 residents living in counties without a local, licensed Medicare insurance broker in their community. This creates a substantial access hurdle for seniors w

    1/21/26 7:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Devanny Earl H Iii converted options into 52,631 shares, increasing direct ownership by 17% to 363,214 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    11/13/25 7:26:51 PM ET
    $SLQT
    Specialty Insurers
    Finance

    Director Hawks Donald L Iii converted options into 52,631 shares, increasing direct ownership by 11% to 513,214 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    11/13/25 7:26:45 PM ET
    $SLQT
    Specialty Insurers
    Finance

    Director Devine Denise L converted options into 52,631 shares, increasing direct ownership by 17% to 371,214 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    11/13/25 7:26:37 PM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Devine Denise L bought $14,460 worth of shares (4,000 units at $3.62), increasing direct ownership by 1% to 318,583 units (SEC Form 4)

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    3/19/25 4:54:26 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form 4: Matthews Joshua Brandon bought $113,295 worth of shares (97,500 units at $1.16), increasing direct ownership by 32% to 400,937 units

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    9/18/23 6:29:01 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form 4: Grant William Thomas Iii bought $179,250 worth of shares (150,000 units at $1.20), increasing direct ownership by 9% to 1,913,851 units

    4 - SelectQuote, Inc. (0001794783) (Issuer)

    9/18/23 6:28:20 PM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Leadership Updates

    Live Leadership Updates

    View All

    SelectQuote Names Ryan Clement as Chief Financial Officer

    Clement has served as Interim CFO since May 2022 SelectQuote, Inc. (NYSE:SLQT) today announced that the Board of Directors appointed Ryan Clement, SVP of Financial Planning & Analysis, to serve as the company's Chief Financial Officer. Clement was named interim CFO in May 2022. CEO Tim Danker commented, "Over the last year, Ryan has excelled as our Interim CFO and has demonstrated both the financial acumen and leadership qualities we are looking for in the company's next permanent CFO. Ryan has played a critical role in our strategic redesign that has vastly improved SelectQuote's operating results and financial stability and positions the company to execute on our objectives in the futur

    2/22/23 8:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Financials

    Live finance-specific insights

    View All

    SelectQuote, Inc. Reports Second Quarter of Fiscal Year 2026 Results

    Second Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights Revenue of $537.1 million Net income of $69.3 million Adjusted EBITDA* of $84.7 million Fiscal Year 2026 Guidance Ranges: Revenue expected in a range of $1.61 billion to $1.71 billion Adjusted EBITDA* expected in a range of $90 million to $100 million Second Quarter Fiscal Year 2026 – Segment Highlights Senior Revenue of $261.5 million Adjusted EBITDA of $102.5 million Approved Medicare Advantage policies of 257,279 Healthcare Services Revenue of $230.7 million Adjusted EBITDA of $0.8 million 113,483 SelectRx members Life Revenue of $43.6 million Adjusted EBITDA of $5.6

    2/5/26 7:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    SelectQuote to Release Fiscal Second Quarter 2026 Earnings on February 5

    SelectQuote, Inc. (NYSE:SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its fiscal second quarter 2026 financial results before market open on Thursday, February 5, 2026. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (February 5, 2026) at 8:00 am ET to discuss the results. We encourage interested parties to access the live webcast of the event via our investor relations website https://ir.selectquote.com/investor-home/default.aspx or via this link. For those interested in dialing into the conferen

    1/22/26 7:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    Pathlight Capital Serves as Administrative Agent on $415,000,000 Senior Secured Credit Facility for SelectQuote, Inc.

    BOSTON, Jan. 13, 2026 /PRNewswire/ -- Pathlight Capital LP ("Pathlight" or "Pathlight Capital") today announced that it is serving as the Administrative Agent on a $415 million senior secured credit facility for SelectQuote, Inc. ("SelectQuote," "SLQT" or the "Company"), a distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform. As part of the facility, Pathlight underwrote and provided a $325 million term loan. Proceeds from the credit facility will be used to refinance existing debt and support ongoing working capital needs. "Ha

    1/13/26 8:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $SLQT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SelectQuote Inc. (Amendment)

    SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)

    1/29/24 3:26:24 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by SelectQuote Inc. (Amendment)

    SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)

    2/14/23 1:42:28 PM ET
    $SLQT
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by SelectQuote Inc. (Amendment)

    SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)

    2/1/23 4:54:05 PM ET
    $SLQT
    Specialty Insurers
    Finance